367 related articles for article (PubMed ID: 32170367)
1. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
2. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
3. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.
Fujino K; Motooka Y; Hassan WA; Ali Abdalla MO; Sato Y; Kudoh S; Hasegawa K; Niimori-Kita K; Kobayashi H; Kubota I; Wakimoto J; Suzuki M; Ito T
Am J Pathol; 2015 Dec; 185(12):3164-77. PubMed ID: 26482608
[TBL] [Abstract][Full Text] [Related]
4. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
[TBL] [Abstract][Full Text] [Related]
5. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
6. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
[TBL] [Abstract][Full Text] [Related]
8. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
9. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].
Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557
[TBL] [Abstract][Full Text] [Related]
10. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer.
Horie M; Miyashita N; Mattsson JSM; Mikami Y; Sandelin M; Brunnström H; Micke P; Nagase T; Saito A
J Pathol; 2018 Oct; 246(2):154-165. PubMed ID: 29876935
[TBL] [Abstract][Full Text] [Related]
11. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
12. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
[TBL] [Abstract][Full Text] [Related]
13. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.
Jiang T; Collins BJ; Jin N; Watkins DN; Brock MV; Matsui W; Nelkin BD; Ball DW
Cancer Res; 2009 Feb; 69(3):845-54. PubMed ID: 19176379
[TBL] [Abstract][Full Text] [Related]
14. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
[TBL] [Abstract][Full Text] [Related]
15. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
Donakonda S; Sinha S; Dighe SN; Rao MRS
Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
[TBL] [Abstract][Full Text] [Related]
16. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
[TBL] [Abstract][Full Text] [Related]
17. ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
Alam SK; Wang L; Ren Y; Hernandez CE; Kosari F; Roden AC; Yang R; Hoeppner LH
Br J Cancer; 2020 Sep; 123(5):819-832. PubMed ID: 32499571
[TBL] [Abstract][Full Text] [Related]
18. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
Tenjin Y; Matsuura K; Kudoh S; Usuki S; Yamada T; Matsuo A; Sato Y; Saito H; Fujino K; Wakimoto J; Ichimura T; Kohrogi H; Sakagami T; Niwa H; Ito T
Lab Invest; 2020 Dec; 100(12):1575-1588. PubMed ID: 32801334
[TBL] [Abstract][Full Text] [Related]
19. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
[TBL] [Abstract][Full Text] [Related]
20. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
